Cargando…
Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
The success of γδ T cell-based immunotherapy, where the cytotoxic activity of circulating γδ T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients’ γδ T cells. A possible in...
Autores principales: | Oberg, Hans-Heinrich, Kellner, Christian, Peipp, Matthias, Sebens, Susanne, Adam-Klages, Sabine, Gramatzki, Martin, Kabelitz, Dieter, Wesch, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269191/ https://www.ncbi.nlm.nih.gov/pubmed/25566256 http://dx.doi.org/10.3389/fimmu.2014.00643 |
Ejemplares similares
-
Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
por: Oberg, Hans H., et al.
Publicado: (2018) -
Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity
por: Gonnermann, Daniel, et al.
Publicado: (2020) -
TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells
por: Tawfik, Doaa, et al.
Publicado: (2019) -
Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells
por: Peters, Christian, et al.
Publicado: (2013) -
Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity
por: Kabelitz, Dieter, et al.
Publicado: (2013)